《Nature,4月8日,Humanity tested》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-04-09
  • The world needs mass at-home serological testing for antibodies elicited by SARS-CoV-2, and rapid and frequent point-of-care testing for the presence of the virus’ RNA in selected populations.

    How did we end up here? Two ways. Gradually, then suddenly. Ernest Hemingway’s passage is a fitting description for humanity’s perception of the exponential growth of COVID-19 cases and deaths (Fig. 1). The worldwide spread of a highly infectious pathogen was only a matter of time, as long warned by many epidemiologists, public health experts, and influential and prominent voices, such as Bill Gates. Yet most of the world was unprepared for such a pandemic; in fact, most Western countries (prominently the United States1) fumbled their response for weeks. Singapore, Hong Kong and Taiwan have shown the world that, to contain the propagation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), governments need to quickly implement aggressive testing (by detecting the viral RNA through polymerase chain reaction (PCR)), the isolation of those infected and the tracing and quarantining of their contacts, while educating their citizens about the need for physical distancing and basic public health measures (in particular, frequent hand-washing and staying at home if feeling unwell).

  • 原文来源:https://www.nature.com/articles/s41551-020-0553-6
相关报告
  • 《Nature,4月8日,Pandemic data challenges》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-04-09
    • Pandemic data challenges Nature Machine Intelligence (2020) The worldwide outbreak of COVID-19 has led to great tragedy and poses unprecedented challenges for countries’ healthcare systems. Data has become an important instrument in the global fight against the unprecedented spread of the virus. But how will we ensure a return to previous forms of data privacy once the pandemic subsides? In a bid to help curb a disastrous course of the disease, scientists are coming together to share research findings and data as quickly and collaboratively as possible. Immediate goals are to understand what measures can slow the spread of COVID-19, which people are the most vulnerable and how to treat critical patients under challenging circumstances. In the medium term, data-driven approaches can help crack the virus’s biology to develop and test vaccines.
  • 《Nature,4月8日,Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-04-09
    • Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus Deepak Jakhar & Ishmeet Kaur Nature Medicine (2020) To the Editor — In March 2020, in the midst of the COVID-19 pandemic1, reports that chloroquine (CQ) can inhibit the growth of severe acute respiratory syndrome coronavirus (SARS-CoV-2)2,3 have brought this molecule into the spotlight. Hydroxychloroquine (HCQS), which is typically used in dermatology clinics for the management of systemic lupus erythematosus (SLE) and has a better clinical safety profile and fewer drug–drug interactions than CQ, has also been demonstrated to have anti-SARS-CoV activity in vitro2,4. Now, amid the speculation regarding the beneficial roles of these molecules in COVID-19 treatment, shortages of CQ and HCQS are feared.